Elsevier

Life Sciences

Volume 38, Issue 23, 9 June 1986, Pages 2103-2110
Life Sciences

Opioid control of LH secretion in humans: Menstrual cycle, menopause and aging reduce effect of naloxone but not of morphine.

https://doi.org/10.1016/0024-3205(86)90209-2Get rights and content

Abstract

A number of studies have been made on the role played by endogenous opioid peptides in the secretion of LH in humans. However no previous studies have compared the effects of the most potent pharmacological agonist and antagonist, morphine and naloxone, in the same subjects. The present study examined the acute effects of injections of morphine and naloxone on plasma LH levels in 30 healthy subjects (18 women and 12 men). Fertile women were subdivided into follicular (n=6) and luteal (n=6) phase groups; the remining 6 were postmenopausal women. The 12 men were sub-divided in two groups of 6 subjects according to age (24–33 years, and over 60 years). There was a two day interval between injection studies in the same subjects. Morphine significantly decreased plasma LH levels in all groups examined (P<0.01). On the other hand, naloxone caused a significant increase in plasma LH levels in fertile women during the luteal phase of the cycle, but not during the follicular phase or in postmenopausal subjects, and in young but not in aged men (P<0.01). These results indicate that in humans there is a change in the activity of the opioids regulating LH secretion during the menstrual cycle, after menopause and in aged men and that these may be studied by the use of naloxone. The inability of naloxone under certain conditions to increase LH levels reflects the decreased activity of the endogenous system, while morphine, being active in all the subjects, seems to be less discriminative, at least in physiological conditions.

References (51)

  • F. Kinoshita et al.

    Life Sci.

    (1982)
  • D.G. Pfeiffer et al.

    Peptides

    (1983)
  • F. Petraglia et al.

    Peptides

    (1985)
  • F. Petraglia et al.

    Fertil. Steril.

    (1985)
  • K.F. Bruni et al.

    Life Sci.

    (1977)
  • M.S. Blank et al.

    Science

    (1979)
  • T.J. Cicero et al.

    Endocrinology

    (1979)
  • R. Schultz et al.

    Nature

    (1981)
  • L.J. Forman et al.
  • T.J. Cicero et al.

    J. Pharmacol. Exper. Ther.

    (1977)
  • F. Kinoshita et al.

    Life Sci.

    (1980)
  • C.A. LEADEM & S.P. KALRA, The Endocrine Soc. Meeting, San Antonio, June 8–10, Abstr....
  • T.J. Cicero et al.

    Brain Res.

    (1980)
  • M. Ferin et al.

    Endocrinology

    (1982)
  • A.E. Panerai et al.

    Life Sci.

    (1983)
  • N. Parvizi et al.

    Nature

    (1980)
  • J.M. Lakoski et al.

    Brain Res.

    (1982)
  • J.H. Johnson et al.

    Life Sci.

    (1982)
  • D.D. Rasmussen et al.

    J. Clin. Endocrinol. Metab.

    (1983)
  • S.P. Kalra et al.

    Endocrinology

    (1981)
  • S.P. Kalra et al.

    Endocrinology

    (1982)
  • T.J. Cicero et al.

    J. Pharm. Exp. Therap.

    (1983)
  • G. Delitala et al.

    Neuroendocrinol.

    (1983)
  • A.E. Panerai et al.

    Endocrinology

    (1985)
  • J.B. Wiesner et al.

    Endocrinology

    (1985)
  • Cited by (64)

    • Impact of the opioid system on the reproductive axis

      2017, Fertility and Sterility
      Citation Excerpt :

      Conversely opiate antagonists, such as naloxone and naltrexone, lead to an increase in LH levels. This effect could only be demonstrated in the luteal phase but not during the follicular phase of the cycle (18, 19). Likewise, no effect on gonadotropin secretion by opioid antagonists was seen in postmenopausal women (20) and in early puberty (21), further underscoring the relationship between the opioid system and circulating sex steroids.

    • Drugs and Pituitary Function

      2011, The Pituitary
    • Hypothalamic amenorrhea: From diagnosis to therapeutical approach

      2010, Annales d'Endocrinologie
      Citation Excerpt :

      This observation might explain the higher rate of success on patients with hypogonadotropic HA and weight loss and/or high-energy consumption. Among the mediator(s) of opiatergic and/or dopaminergic systems [31,37–40] in HA, a role has also been proposed for gamma-aminobutyric acid (GABA), an important modulator of the physiological response to stress or anxiety [41]. In fact, various acute and chronic stressors have been shown to produce a rapid decrease in the activity of GABAergic pathways in primates and in humans [42,43].

    • Drugs and Pituitary Function

      2010, The Pituitary, Third Edition
    View all citing articles on Scopus
    $

    Present address: The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute La Jolla, CA 92037

    View full text